As recombinant IFNβ has been FDA approved for multiple sclerosis and antibodies targeting the IFNβ/IFNAR1 pathway have been fully developed in the context of autoimmunity57, these results can be readily translated into the clinic. Here, IFNAR1 is linked to multiple sclerosis.